Patients who engaged most with a targeted messaging platform as part of a hospital-wide prehabilitation program experienced significantly fewer postoperative complications after plastic surgery. These...
Patients who engaged most with a targeted messaging platform as part of a hospital-wide prehabilitation program experienced significantly fewer postoperative complications after plastic surgery. These...
Patients who engaged most with a targeted messaging platform as part of a hospital-wide prehabilitation program experienced significantly fewer postoperative complications after plastic surgery. These...
Patients who engaged most with a targeted messaging platform as part of a hospital-wide prehabilitation program experienced significantly fewer postoperative complications after plastic surgery. These...
Patients who engaged most with a targeted messaging platform as part of a hospital-wide prehabilitation program experienced significantly fewer postoperative complications after plastic surgery. These...
A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...
A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...
A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...
A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...
A phase 2 trial from the University of Miami evaluated whether combining iberdomide with carfilzomib, daratumumab, and dexamethasone could induce deep responses—including MRD-negativity—in patients with...
